The estimated Net Worth of Pamela A Simonton is at least $506 Thousand dollars as of 15 February 2014. Pamela Simonton owns over 1,875 units of Exelixis Inc stock worth over $506,343 and over the last 21 years Pamela sold EXEL stock worth over $0.
Pamela has made over 21 trades of the Exelixis Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Pamela exercised 1,875 units of EXEL stock worth $49,931 on 15 February 2014.
The largest trade Pamela's ever made was exercising 10,000 units of Exelixis Inc stock on 24 April 2006 worth over $63,000. On average, Pamela trades about 2,988 units every 90 days since 2003. As of 15 February 2014 Pamela still owns at least 19,014 units of Exelixis Inc stock.
You can see the complete history of Pamela Simonton stock trades at the bottom of the page.
Pamela's mailing address filed with the SEC is C/O EXELIXIS, INC., 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRANCISCO, X1, 94083-0511.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey, and Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: